department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Eylea · pharmadog

pharmadog
drugs
Eylea

drug

patient view →

Eylea

Marketedupdated 2mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Eylea

generic

aflibercept

indication

Diabetic Macular Edema

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval40 co-mentions · 15 sources
drugEYLEA HD32 co-mentions · 15 sources
drugaflibercept biosimilar15 co-mentions · 10 sources
drugYESAFILI14 co-mentions · 7 sources
drugOPUVIZ8 co-mentions · 4 sources
drugENZEEVU6 co-mentions · 3 sources
companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
companySandoz Inc3 co-mentions · 3 sources

Trials studying Eylea

phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56active not recruitingn=400
—Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)recruitingn=480
phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)recruitingn=960
phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)recruitingn=960
—Real-world Study of Aflibercept 8 mg in nAMDrecruitingn=300
phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMErecruitingn=240
phase4Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)not yet recruitingn=186
phase2Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)active not recruitingn=139

more trials →